Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis

被引：5
|
作者：
Conant, Marjorie M. [1 ]
Sha, Beverly E. [1 ]
Proia, Laurie A. [1 ]
机构：
[1] Rush Univ, Div Infect Dis, Med Ctr, Chicago, IL 60612 USA
来源：
MYCOSES | 2015年 / 58卷 / 05期
关键词：
Posaconazole; antifungal therapy; aspergillus; invasive mould infection; PHARMACOKINETICS; SAFETY; TRIAL;
D O I：
10.1111/myc.12309
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
A 65-year-old man developed Aspergillus brain abscesses following surgical resection of a sinus aspergilloma. He was treated with voriconazole for 1year but infection recurred. We elected to treat with posaconazole delayed-release tablets, currently only indicated as antifungal prophylaxis in high-risk patients. A maintenance dose of 300mg Q24h resulted in a therapeutic serum concentration and appears safe and clinically effective thus far. This is the first report of successful use of posaconazole tablets for treatment of invasive aspergillosis.
引用
收藏
页码：313 / 314
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
    Wiederhold, Nathan P.
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 : 1 - 8
  • [2] Treatment of Aspergillus fumigatus infection with posaconazole delayed-release tablets
    Shearin, Suzanne
    Bell, Tara
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (13) : 958 - 961
  • [3] Serum Levels of Crushed Posaconazole Delayed-Release Tablets
    Mason, Mathew J.
    McDaneld, Patrick M.
    Musick, William L.
    Kontoyiannis, Dimitrios P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [4] Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis
    Kosmidis, Chris
    Rodriguez-Goncer, Isabel
    Rautemaa-Richardson, Riina
    Richardson, Malcolm D.
    Moore, Caroline B.
    Denning, David W.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (04) : 1056 - 1061
  • [5] Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
    Leelawattanachai, Pannee
    Montakantikul, Preecha
    Nosoongnoen, Wichit
    Chayakulkeeree, Methee
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 589 - 595
  • [6] The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf
    Marques, Goncalo N.
    Silva, Nuno U.
    Leal, Miriam O.
    Flanagan, Carla A.
    [J]. MEDICAL MYCOLOGY CASE REPORTS, 2021, 32 : 77 - 80
  • [7] Successful enteral administration of crushed posaconazole delayed-release tablets in children
    Bio, Laura L.
    Hiroshima, Lyndsie
    Schwenk, Hayden T.
    Green, Sean
    [J]. PEDIATRIC BLOOD & CANCER, 2024, 71 (02)
  • [8] Posaconazole delayed-release tablets in paediatric haematology-oncology patients
    Mauro, Margherita
    Colombini, Antonella
    Perruccio, Katia
    Zama, Daniele
    D'Amico, Maria Rosaria
    Calore, Elisabetta
    Carraro, Francesca
    Muggeo, Paola
    Tridello, Gloria
    Baretta, Valentina
    Cesaro, Simone
    [J]. MYCOSES, 2020, 63 (06) : 604 - 609
  • [9] Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents
    Tragiannidis, Athanasios
    Herbrueggen, Heidrun
    Ahlmann, Martina
    Vasileiou, Eleni
    Gastine, Silke
    Thorer, Heike
    Froehlich, Birgit
    Mueller, Carsten
    Groll, Andreas H.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (12) : 3573 - 3578
  • [10] Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis
    Manesh, Abi
    Devasagayam, Emily
    Bhanuprasad, Kundakarla
    Mathew, Sumith K.
    Karthik, Rajiv
    Mathew, Binu S.
    Varghese, George M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (12)
12345